Who is sponsoring NCT00286182?

NCT00286182 is sponsored by Mathew S. Maurer.

What drugs are being tested in NCT00286182?

Interventions: Erythropoietin alpha, Placebo.

What is the status of NCT00286182?

NCT00286182 is currently COMPLETED.

Last reviewed 2017-01-30 · How we verify

Efficacy of Treating Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF) on Ventricular Function, Exercise Capacity and Health Status

NCT00286182 Phase 2 COMPLETED Results posted

The purpose of this study is to determine if treating anemia with subcutaneous erythropoetin in patients with heart failure and a preserved ejection fraction (HFPEF) will be associated with reverse ventricular remodeling, significant improvements in exercise capacity, and improved health status, as compared with placebo.

Details

Lead sponsor	Mathew S. Maurer
Phase	Phase 2
Status	COMPLETED
Enrolment	56
Start date	2007-07
Completion	2012-11

Conditions

Anemia

Interventions

Erythropoietin alpha
Placebo

Primary outcomes

Change in Left Ventricular End-diastolic Volume — Baseline and 6 month
This outcome measure is collected using a three dimensional echocardiography.

Countries

United States